Q2 Earnings Estimate for Certara Issued By Leerink Partnrs

Certara, Inc. (NASDAQ:CERT - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Certara in a report issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $0.06 per share for the quarter, down from their prior estimate of $0.07. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2027 earnings at $0.38 EPS.

A number of other research analysts also recently weighed in on CERT. JMP Securities reiterated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Robert W. Baird upped their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. KeyCorp boosted their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Finally, Morgan Stanley initiated coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price target for the company. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.71.

Certara Price Performance

CERT stock traded up $0.03 on Thursday, hitting $11.50. 1,172,046 shares of the company's stock traded hands, compared to its average volume of 1,468,274. The stock has a fifty day moving average of $11.50 and a 200-day moving average of $11.86. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of 34.76 and a beta of 1.43. Certara has a 1-year low of $8.64 and a 1-year high of $16.93. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The business's revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 earnings per share.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc boosted its position in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after acquiring an additional 1,866 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Certara during the first quarter valued at about $31,000. Wells Fargo & Company MN raised its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Certara in the first quarter valued at about $39,000. Finally, Johnson Financial Group Inc. acquired a new stake in Certara during the fourth quarter worth about $47,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.